Investors & Media

Transformative science, targeted medicines

We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

News release details

Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit

November 28, 2023 at 8:00 AM EST

CAMBRIDGE, Mass., Nov. 28, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 5, 2023 at 11:00 a.m. ET.

A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.

About Blueprint Medicines 

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we have brought our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for mast cell disorders, including systemic mastocytosis and chronic urticaria, breast cancer and other cancers vulnerable to CDK2 inhibition, as well as EGFR-mutant lung cancer. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-jmp-securities-hematology-and-oncology-summit-301996028.html

SOURCE Blueprint Medicines Corporation

Investor Relations Contact: Jenna Cohen, 857-209-3147, ir@blueprintmedicines.com; Media Relations Contact: Andrew Law, 617-844-8205, media@blueprintmedicines.com